Seres Therapeutics, Inc.
Assets & Liabilities
| Period | Total Liabilities | Total Assets | Cash on Hand |
|---|---|---|---|
| Mar 2017 | $133.4M | $244.9M | $41.9M |
| Jun 2017 | $128.4M | $216.3M | $33.6M |
| Sep 2017 | $126.4M | $211.9M | $46.0M |
| Dec 2017 | $128.8M | $189.5M | $36.1M |
| Mar 2018 | $149.4M | $159.4M | $47.2M |
| Jun 2018 | $146.2M | $133.0M | $58.0M |
| Sep 2018 | $139.6M | $109.0M | $55.7M |
| Dec 2018 | $168.5M | $120.5M | $85.8M |
| Mar 2019 | $176.9M | $107.0M | $53.6M |
| Jun 2019 | $164.1M | $146.1M | $102.2M |
| Sep 2019 | $156.4M | $124.2M | $49.3M |
| Dec 2019 | $180.8M | $132.4M | $65.1M |
| Mar 2020 | $172.3M | $110.6M | $54.9M |
| Jun 2020 | $166.3M | $100.7M | $61.5M |
| Sep 2020 | $168.1M | $356.2M | $207.3M |
| Dec 2020 | $168.2M | $342.9M | $116.0M |
| Mar 2021 | $162.0M | $305.7M | $66.6M |
| Jun 2021 | $168.6M | $269.6M | $74.0M |
| Sep 2021 | $220.6M | $396.3M | $227.5M |
| Dec 2021 | $223.4M | $354.9M | $180.0M |
| Mar 2022 | $238.9M | $319.9M | $153.2M |
| Jun 2022 | $250.1M | $273.2M | $126.8M |
| Sep 2022 | $244.3M | $311.9M | $205.4M |
| Dec 2022 | $338.0M | $348.8M | $163.0M |
| Mar 2023 | $318.1M | $270.2M | $94.8M |
| Jun 2023 | $383.8M | $406.4M | $229.5M |
| Sep 2023 | $382.8M | $367.7M | $169.9M |
| Dec 2023 | $403.5M | $358.6M | $128.0M |
| Mar 2024 | $401.0M | $341.3M | $111.2M |
| Jun 2024 | $408.8M | $321.7M | $71.2M |
| Sep 2024 | $154.8M | $178.7M | $66.8M |
| Dec 2024 | $126.0M | $139.8M | $30.8M |
| Mar 2025 | $113.7M | $164.2M | $58.8M |
| Jun 2025 | $110.9M | $143.8M | $45.4M |
| Sep 2025 | $99.8M | $143.5M | $47.6M |
| Dec 2025 | $94.0M | $138.2M | $45.8M |
| Mar 2026 | $91.1M | $117.6M | $29.8M |
| Jun 2026 | $67.1M | $101.6M | $15.6M |